Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00105-016-3889-9 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Recalcitrant Female Pattern Hair Loss Like Alopecia Unveils Unexpected Rare Entity.
Clin Cosmet Investig Dermatol
January 2025
Lugansk state medical University, Department of Pathology, Rivne, Ukraine.
Introduction: Marie-Unna hereditary hypotrichosis (MUHH) is an autosomal dominant disorder characterized by a specific pattern of hair loss. Initially described in 1925 by Marie-Unna in a German family spanning over seven generations, MUHH represents a previously unidentified form of congenital hypotrichosis. It typically presents as sparse hair at birth with a coarse texture, followed by regrowth during childhood then, finally, gradual hair loss at puberty, resembling pattern of androgenetic alopecia.
View Article and Find Full Text PDFReal-World Experience of Clascoterone Cream 1% in Acne Management: Case Series and Canadian Experience.
Clin Cosmet Investig Dermatol
January 2025
Western University, London, ON, Canada.
Acne vulgaris is a globally prevalent dermatological condition associated with substantial physical and psychological burden. Although acne typically presents during adolescence, it is a chronic condition that also affects many adults. Despite the spectrum of treatments available for acne, limitations in tolerability and safety concerns can present challenges for the use of conventional medications in clinical practice.
View Article and Find Full Text PDFAdverse events associated with aromatase inhibitors: an analysis of real-world datasets and drug-gene interaction network.
Expert Opin Drug Saf
November 2024
Department of Obstetrics and Gynecology, Yancheng TCM Hospital Affiliated to Nanjing University of Chinese Medicine; Yancheng TCM Hospital, Jiangsu, China.
Article Synopsis
- - The study evaluated the safety of aromatase inhibitors (AIs) used for treating postmenopausal hormone receptor positive breast cancer by analyzing adverse event reports from the FDA between 2004 and 2023.
- - Researchers collected 7,933 reports which identified common adverse reactions linked to AIs, such as antiphospholipid syndrome for anastrozole and androgenetic alopecia for letrozole, among others.
- - The findings stress existing safety concerns with AIs in clinical settings, underscoring the need for thorough monitoring and reporting of their adverse effects.
Hair Loss: Diagnosis and Treatment.
Am Fam Physician
September 2024
Boston University Chobanian and Avedisian School of Medicine, Boston, MA.
Article Synopsis
- Over 80 million people in the U.S. experience hair loss, classified mainly as nonscarring alopecias (diffuse, patterned, or focal), with androgenetic alopecia being the most common.
- Treatment options vary: minoxidil is the first line for patterned hair loss, while focal hair loss may require corticosteroids or oral antifungals depending on the cause.
- Hair loss can lead to anxiety, depression, and lower quality of life, emphasizing the importance of patient education on treatment options and realistic expectations.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!